JP2023528435A5 - - Google Patents
Info
- Publication number
- JP2023528435A5 JP2023528435A5 JP2022574357A JP2022574357A JP2023528435A5 JP 2023528435 A5 JP2023528435 A5 JP 2023528435A5 JP 2022574357 A JP2022574357 A JP 2022574357A JP 2022574357 A JP2022574357 A JP 2022574357A JP 2023528435 A5 JP2023528435 A5 JP 2023528435A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- spacer
- bond
- optionally
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063033926P | 2020-06-03 | 2020-06-03 | |
| US63/033,926 | 2020-06-03 | ||
| US202063119717P | 2020-12-01 | 2020-12-01 | |
| US63/119,717 | 2020-12-01 | ||
| PCT/US2021/035603 WO2021247800A2 (en) | 2020-06-03 | 2021-06-03 | Treatment of neurological diseases using modulators of gene transcripts |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023528435A JP2023528435A (ja) | 2023-07-04 |
| JP2023528435A5 true JP2023528435A5 (enExample) | 2024-06-10 |
Family
ID=78831722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574357A Withdrawn JP2023528435A (ja) | 2020-06-03 | 2021-06-03 | 遺伝子転写物のモジュレーターを使用する神経学的疾患の処置 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230235332A1 (enExample) |
| EP (1) | EP4162051A4 (enExample) |
| JP (1) | JP2023528435A (enExample) |
| KR (1) | KR20230043819A (enExample) |
| AU (1) | AU2021284360A1 (enExample) |
| CA (1) | CA3185488A1 (enExample) |
| IL (1) | IL298647A (enExample) |
| WO (1) | WO2021247800A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024006612A (es) * | 2021-12-03 | 2024-06-12 | Quralis Corp | Oligonucleotidos antisentido de cambio de empalme con estructuras quimicas modificadas. |
| GB202208387D0 (en) * | 2022-06-08 | 2022-07-20 | Ucl Business Ltd | Modified U7 snRNA construct |
| WO2026080323A1 (en) | 2024-10-09 | 2026-04-16 | Quralis Corporation | Treatment of neurological diseases using modulators of unc13a gene transcripts |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002514909A (ja) * | 1996-09-24 | 2002-05-21 | ラピジーン，インコーポレイテッド | ハイブリダイゼーション特異性を増強するための組成物および方法 |
| US20110046200A1 (en) * | 2004-08-03 | 2011-02-24 | Michael T Howard | Use of antisense oligonucleotides to effect translation modulation |
| EP3702460A1 (en) * | 2010-11-12 | 2020-09-02 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| CA3103429A1 (en) * | 2018-06-14 | 2019-12-19 | Don W. Cleveland | Compounds and methods for increasing stmn2 expression |
| US12496327B2 (en) * | 2019-01-14 | 2025-12-16 | President And Fellows Of Harvard College | Methods and compositions for restoring STMN2 levels |
| WO2020247419A2 (en) * | 2019-06-03 | 2020-12-10 | Quralis Corporation | Oligonucleotides and methods of use for treating neurological diseases |
| EP4127172A4 (en) * | 2020-03-25 | 2025-06-04 | President and Fellows of Harvard College | Methods and compositions for restoring STMN2 levels |
-
2021
- 2021-06-03 WO PCT/US2021/035603 patent/WO2021247800A2/en not_active Ceased
- 2021-06-03 US US17/928,708 patent/US20230235332A1/en active Pending
- 2021-06-03 IL IL298647A patent/IL298647A/en unknown
- 2021-06-03 EP EP21817154.4A patent/EP4162051A4/en active Pending
- 2021-06-03 KR KR1020237000041A patent/KR20230043819A/ko active Pending
- 2021-06-03 JP JP2022574357A patent/JP2023528435A/ja not_active Withdrawn
- 2021-06-03 AU AU2021284360A patent/AU2021284360A1/en active Pending
- 2021-06-03 CA CA3185488A patent/CA3185488A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022536085A5 (enExample) | ||
| CN111373043B (zh) | 用于降低snca表达的化合物和方法 | |
| KR100991975B1 (ko) | 핵산을 기본으로 하는 화합물 및 이의 사용방법 | |
| JP2024543214A5 (enExample) | ||
| JP2022515744A5 (enExample) | ||
| JP2013525330A5 (enExample) | ||
| JP2008510019A5 (enExample) | ||
| US20250051766A1 (en) | Treatment of neurological diseases using modulators of unc13a gene transcripts | |
| IL313205A (en) | Microbial consortia | |
| JP2022520986A5 (enExample) | ||
| EP4441226A2 (en) | Splice switcher antisense oligonucleotides with modified backbone chemistries | |
| JP2021515784A (ja) | 修飾オリゴヌクレオチド及びタウオパチーにおける使用方法 | |
| JP2023536472A5 (enExample) | ||
| CN120505310A (zh) | 用于调节smn2的化合物和方法 | |
| JP2024540537A5 (enExample) | ||
| US20230235332A1 (en) | Treatment of neurological diseases using modulators of gene transcripts | |
| JP2025518487A5 (enExample) | ||
| JP2025501682A5 (enExample) | ||
| JP2025501682A (ja) | 改変された骨格化学を有するギャップマーアンチセンスオリゴヌクレオチド | |
| JP2023532518A5 (enExample) | ||
| CN121986163A (zh) | 修饰的unc13a寡核苷酸 | |
| RU2021138237A (ru) | Олигонуклеотиды и способы применения для лечения неврологических заболеваний | |
| JP2023545041A (ja) | Ｄｍｄ患者におけるエクソン５１スキッピングによるジストロフィンレスキューのためのオリゴマー化合物 | |
| HK40121031A (en) | Splice switcher antisense oligonucleotides with modified backbone chemistries | |
| EA053024B1 (ru) | Антисмысловые олигонуклеотиды-переключатели сплайсинга с модифицированной химией скелета |